Bisphosphonates and time to osteonecrosis development

Oncologist

Volumn 14, Issue 11, 2009, Pages 1154-1166

  Palaska, Pinelopi Kleio ^a   Cartsos, Vassiliki ^b   Zavras, Athanasios I ^c,d  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

^c New York Presbyterian Hospital   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bisphosphonates; BONJ; Cancer; Dose; Osteoporosis; Time

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

AGING; ARTICLE; BONE CANCER; BONE METASTASIS; CANCER PATIENT; CIGARETTE SMOKING; COMORBIDITY; CONTINUING EDUCATION; CORTICOSTEROID THERAPY; DENTAL SURGERY; DIABETES MELLITUS; DISEASE COURSE; GENOTYPE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OBESITY; ONCOLOGY; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TIME; VITAMIN D DEFICIENCY;

DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS; TIME FACTORS;

EID: 75449117669     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0115     Document Type: Article

References (102)

1. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws:Aclinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35:588-593.
2. Migliorati CA, Schubert MM, Peterson DE et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
3. Edwards BJ, Hellstein JW, Jacobsen PL et al.; American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008;139:1674-1677.
4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
5. ProSciTech. Descriptions/Definitions of Exposure Levels. Available at http://www.proscitech.com.au/cataloguex/exposure.asp, accessed June 10, 2009.
6. Roche. Trial Results Search: Clinical Trial Result Information. Protocol number ML17632. Available at http://www.roche-trials.com/patient/trialresults/ stur162.html, accessed June 10, 2009.
7. Marx RE, Sawatari Y, Fortin M et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
8. Lazarovici TS, Yahalom R, Taicher S et al. Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients. J Oral Maxillofac Surg 2009;67:850-855.
9. Mavrokokki T, Cheng A, Stein B et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423.
10. Van den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 2007;19:315-322.
11. Kyrgidis A, Vahtsevanos K, Koloutsos G et al. Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients. J Clin Oncol 2008;26:4634-4638.
12. Saussez S, Javadian R, Hupin C et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: A Belgian case series. Laryngoscope 2009;119:323-329.
13. Boonyapakorn T, Schirmer I, Reichart PA et al. Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-869.
14. Pozzi S, Marcheselli R, Sacchi S et al.; Gruppo Italiano Studio Linfomi. Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007;48:56-64.
15. Dannemann C, Grätz KW, Riener MO et al. Jaw osteonecrosis related to bisphosphonate therapy: A severe secondary disorder. Bone 2007;40:828-834.
16. Merigo E, Manfredi M, Meleti M et al. Bone necrosis of the jaws associated with bisphosphonate treatment: A report of twenty-nine cases. Acta Biomed 2006;77:109-117.
17. Hoff AO, Toth BB, Altundag K et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24(18 suppl):8528.
18. Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-836.
19. Bagan JV, Jimenez Y, Murillo J et al. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006;42:327-329.
20. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate- associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 2007;138:971-977.
21. Thakkar SG, Isada C, Smith J et al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 2006;23:51-56.
22. Fehm T, Beck V, BanysMet al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009;112:605-609.
23. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-971.
24. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182:417-418.
25. Ibrahim T, Barbanti F, Giorgio-Marrano G et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: A retrospective study. The Oncologist 2008;13:330-336.
26. Ficarra G, Beninati F, Rubino I et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-1128.
27. Vieillard MH, Maes JM, Penel G et al. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 2008;75:34-40.
28. Ortega C, Faggiuolo R, Vormola R et al. Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta Oncol 2006;45:216-217.
29. Walter C, Grötz KA, Kunkel M et al. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15:197-202.
30. Walter C, Al-Nawas B, Grötz KA et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-1072.
31. Clarke BM, Boyette J, Vural E et al. Bisphosphonates and jaw osteonecrosis: The UAMS experience. Otolaryngol Head Neck Surg 2007;136:396-400.
32. Cetiner S, Sucak GT, Kahraman SA et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab 2009;27:435-443.
33. Raje N, Woo SB, Hande K et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 2008;14:2387-2395.
34. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition. J Am Dent Assoc 2005;136:1675-1681.
35. Capalbo S, Delia M, Diomede D et al. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: Paradoxical complication of treatment of bone lesions in multiple myeloma patients. Int J Hematol 2006;83:439-442.
36. Sanna G, Zampino MG, Pelosi G et al. Jaw avascular bone necrosis associated with long-term use of biphosphonates. Ann Oncol 2005;16:1207-1208.
37. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-514.
38. Lobato JV, Maurício AC, Rodrigues JM et al. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate. J Plast Reconstr Aesthet Surg 2008;61:99-106.
39. Herbozo PJ, Briones DL, Ferres AJ et al. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:1650-1654.
40. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-1107.
41. Cafro AM, Barbarano L, Nosari AM et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma 2008;8:111-116.
42. García Sáenz JA, López Tarruella S, García Paredes B et al. Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med Oral Patol Oral Cir Bucal 2007;12:E351-E356.
43. Kumar SK, Meru M, Sedghizadeh PP. Osteonecrosis of the jaws secondary to bisphosphonate therapy: A case series. J Contemp Dent Pract 2008;9:63-69.
44. Kraj M, Pogłód R, Maj S et al. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates. Acta Pol Pharm 2006;63:450-452.
45. Merigo E, Manfredi M, Meleti M et al. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): A four-case report. J Oral Pathol Med 2005;34:613-617.
46. Mawardi H, Treister N, Richardson P et al. Sinus tracts - an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg 2009;67:593-601.
47. Curi MM, Cossolin GS, Koga DH et al. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases. J Oral Maxillofac Surg 2007;65:349-355.
48. Pongchaiyakul C, Auraiwan K, Kotruchin P et al. Bisphosphonate-related osteonecrosis of the jaws (ONJ): A report of two cases. J Med Assoc Thai 2007;90:2494-2498.
49. Reiriz AB, De Zorzi Pde M, Lovat CP. Bisphosphonates and osteonecrosis of the jaw: A case report. Clinics (Sao Paulo) 2008;63:281-284.
50. Leite AF, Figueiredo PT, Melo NS et al. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:14-21.
51. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005;66:658.
52. Statz TA, Guthmiller JM, Humbert LA et al. Intravenous bisphosphonate-associated osteonecrosis of the jaw. J Periodontol 2007;78:2203-2208.
53. Goldman ML, Denduluri N, Berman AW et al. A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology 2006;71:306-308.
54. Markiewicz MR, Margarone JE 3rd, Campbell JH et al. Bisphosphonate- associated osteonecrosis of the jaws: A review of current knowledge. J Am Dent Assoc 2005;136:1669-1674.
55. Sarathy AP, Bourgeois SL Jr, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: Two case reports. J Endod 2005;31:759-763.
56. Borrás-Blasco J, Rosique-Robles D, Giner-Marco V et al. Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid. J Clin Pharm Ther 2007;32:651-654.
57. Soileau KM. Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol 2006;77:738-743.
58. Guarneri V, Donati S, Nicolini M et al. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. The Oncologist 2005;10:842-848.
59. Zarychanski R, Elphee E, Walton P et al. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006;81:73-75.
60. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust 2005;182:413-415.
61. Mouri Y, Yoshida M, Nakano S et al. A case of osteonecrosis of the jaw in a breast cancer patient with bone metastases receiving long-term treatment with bisphosphonates. Breast Cancer 2009;16:147-150.
62. Langer CJ. Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: Case report. Support Cancer Ther 2006;3:122-124.
63. Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R et al. Osteonecrosis of the jaws and bisphosphonates. Report of three cases. Med Oral Patol Oral Cir Bucal 2006;11:E76-E79.
64. Lugassy G, Shaham R, Nemets A et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity. Am J Med 2004;117:440-441.
65. Treister N, Woo SB. Images in clinical medicine. Bisphosphonate- associated osteonecrosis of the jaw. N Engl J Med 2006;355:2348.
66. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
67. Aguiar Bujanda D, Bohn Sarmiento U, Cabréra Suárez MA et al. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007;18:556-560.
68. Friedrich RE, Blake FA. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: A report on four patients. Anticancer Res 2007;27:1841-1845.
69. Bedogni A, Saia G, RagazzoMet al. Bisphosphonate-associated osteonecrosis can hide jaw metastases. Bone 2007;41:942-945.
70. Grasko JM, Herrmann RP, Vasikaran SD. Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates. J Oral Maxillofac Surg 2009;67:645-649.
71. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-2410.
72. Yarom N, Yahalom R, Shoshani Y et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-1370.
73. Brooks JK, Gilson AJ, Sindler AJ et al. Osteonecrosis of the jaws associated with use of risedronate: Report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:780-786.
74. Siegel MA, Migliorati CA, Velez I et al. Exposed bone in the palate. J Am Dent Assoc 2007;138:1341-1343.
75. Grana J, Mahia IV, Meizoso MO et al. Multiple osteonecrosis of the jaw, oral bisphosphonate therapy and refractory rheumatoid arthritis (Pathological fracture associated with ONJ and BP use for osteoporosis). Clin Exp Rheumatol 2008;26:384-385.
76. Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 2006;137:1115-1119; quiz 1169-1170.
77. Levin L, Laviv A, Schwartz-Arad D. Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc 2007;138:1218-1220.
78. Engroff SL, Coletti D. Bisphosphonate related osteonecrosis of the palate: Report of a case managed with free tissue transfer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:580-582.
79. Pires FR, Miranda A, Cardoso ES et al. Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Dis 2005;11:365-369.
80. Sonis ST, Watkins BA, Lyng GD et al. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 2009;45:164-172.
81. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg 2008;66:625-631.
82. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006;24:945-952.
83. Khamaisi M, Regev E, Yarom N et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-1175.
84. Brown JJ, Ramalingam L, Zacharin MR. Bisphosphonate-associated osteonecrosis of the jaw: Does it occur in children? Clin Endocrinol (Oxf) 2008;68:863-867.
85. Chahine C, Cheung MS, HeadTWet al. Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 2008;153:719-720.
86. Greuter S, Schmid F, Ruhstaller T et al. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008;19:2091-2092.
87. Estilo CL, Fornier M, Farooki A et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-4038.
88. Feller L, Wood NH, Raubenheimer EJ et al. Alveolar bone necrosis and spontaneous tooth exfoliation in an HIV-seropositive subject with herpes zoster. SADJ 2008;63:106-110.
89. Siwamogstham P, Kuansuwan C, Reichart PA. Herpes zoster in HIV infection with osteonecrosis of the jaw and tooth exfoliation. Oral Dis 2006;12:500-505.
90. Meer S, Coleman H, Altini M et al. Mandibular osteomyelitis and tooth exfoliation following zoster-CMV co-infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:70-75.
91. Papapoulos SE. Bisphosphonates: How do they work? Best Pract Res Clin Endocrinol Metab 2008;22:831-847.
92. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bisphossy jaw): Is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-689.
93. Allen MR. Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact 2007;7:358-360.
94. Nishimura I, Hokugo A, Adams JS et al. Vitamin D-Insufficient, Bisphosphonate-Treatment Rats Developed Osteonecrosis of the Jaw. Available at http://iadr.confex.com/iadr/2008Dallas/techprogram/abstract-101636.htm, accessed June 5, 2009.
95. Ardine M, Generali D, Donadio M et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006;17:1336-1337.
96. Berruti A, Ortega C, Fusco V. Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-1072. Eur Urol 2009;55:e61-e62.
97. Berruti A, Dogliotti L, Tampellini M et al. Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. J Clin Oncol 2006;24(18 suppl):8610.
98. Chen L, Cencioni MT, Angelini DF et al. Transcriptional profiling of gamma delta T cells identifies a role for vitamin D in the immunoregulation of the V gamma 9V delta 2 response to phosphate-containing ligands. J Immunol 2005;174:6144-6152.
99. Allegra A, Oteri G, Nastro E et al. Patients with bisphosphonates- associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 2007;25:164-169.
100. Landesberg R, Cozin M, Cremers S et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-847.
101. Deng X, Tamai R, Endo Y et al. Alendronate augments interleukin-1β release from macrophages infected with periodontal pathogenic bacteria through activation of caspase-1. Toxicol Appl Pharmacol 2009;235:97-104.
102. Timuraǧaoǧlu A, Ozkaynak C, Tuzuner S et al. Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib. Acta Haematol 2007;118:203-204.